Proxy Results, Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 11, 2025, at the Annual Meeting of the Shareholders of MIRA Pharmaceuticals, Inc. (the "Company"), the Company's shareholders approved Company's 2022 Omnibus Incentive Plan (the "Plan") to (1) increase the number of shares reserved under the Plan from 5,000,000 to 8,000,000, and (2) to allow for the repricing of options or stock appreciation rights ("SARs"), including reducing the exercise or grant price of an outstanding options or SAR, as determined by the Administrator of the Plan. Additional details about the Plan are set forth in the Company's definitive proxy statement filed on August 8, 2025. The form of amended Plan is included as an exhibit in this report on Form 8-K.

Item 5.07. Submission of a Matter to a Vote of Security Holders.

On September 11, 2025, MIRA Pharmaceuticals, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). The record date for stockholders entitled to notice of the Annual Meeting was July 21, 2025 (the "Record Date"). As of the Record Date, there were 19,069,315 shares of common stock, par value $0.0001 per share ("Common Stock"), of the Company outstanding. Each share of Common Stock represents one vote that could be voted on each matter that came before the Annual Meeting.

At the Annual Meeting, 10,588,211.00 shares of Common Stock were represented and voted by proxy, constituting a quorum for the Annual Meeting. The 10,588,211 votes represented equaled approximately 55.52% of the outstanding possible votes.

At the Annual Meeting, five proposals were submitted to the Company's stockholders. The proposals are described in more detail in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on August 8, 2025. Each proposal was approved by the Company's stockholders, including the proposal to approve the acquisition of SKNY Pharmaceuticals, Inc. ("SKNY").

The approval of the SKNY transaction represents a significant milestone for the Company. At closing, SKNY will contribute $5 million in cash or assets to MIRA. Independent valuation analyses conducted by Moore Financial Consulting assigned enterprise values of approximately $30.5 million for SKNY (based on a risk-adjusted net present value of SKNY-1) and $30 million for MIRA, supporting a combined enterprise value of more than $60 million for the merged entity. The Company expects the transaction to close shortly, subject to customary closing conditions.

The final voting results were as follows:

Proposal 1

The Company's stockholders approved the issuance of shares of MIRA Common Stock or other securities of MIRA pursuant to the Merger as defined below, which will represent (or are convertible into) more than 20% of the shares of MIRA Common Stock outstanding immediately prior to the Merger, pursuant to Nasdaq Listing Rule 5635(a), based on the voting results set forth below.